Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
A large subgroup of around 25% of schizophrenia patients suffers from obsessive-compulsive symptoms (OCS) and about 12% fulfill the diagnostic criteria of an obsessive-compulsive disorder (OCD). The additional occurrence of OCS is associated with high subjective burden of disease, additional neurocognitive impairment, poorer social and vocational functioning, greater service utilization and high levels of anxiety and depression. Comorbid patients can be assigned to heterogeneous subgroups. One hypothesis assumes that second generation antipsychotics (SGAs), most importantly clozapine, might aggravate or even induce second-onset OCS. Several arguments support this assumption, most importantly the observed chronological order of first psychotic manifestation, start of treatment with clozapine and onset of OCS. In addition, correlations between OCS-severity and dose and serum levels and duration of clozapine treatment hint toward a dose-dependent side effect. It has been hypothesized that genetic risk-factors dispose patients with schizophrenia to develop OCS. One study in a South Korean sample reported associations with polymorphisms in the gene SLC1A1 (solute carrier family 1A1) and SGA-induced OCS. However, this finding could not be replicated in European patients. Preliminary results also suggest an involvement of polymorphisms in the BDNF gene (brain-derived neurotrophic factor) and an interaction between markers of SLC1A1 and the gene DLGAP3 (disc large associated protein 3) as well as GRIN2B (N-methyl-D-aspartate receptor subunit 2B). Further research of well-defined samples, in particular studies investigating possible interactions of genetic risk-constellations and pharmacodynamic properties, are needed to clarify the assumed development of SGA-induced OCS. Results might improve pathogenic concepts and facilitate the definition of at risk populations, early detection and monitoring of OCS as well as multimodal therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524
The environment and schizophrenia
van Os, J., Kenis, G., & Rutten, B. P. F. (2010) · Nature · doi:10.1038/nature09563 · Cited by 1,572 · cited 2×
“These could include migration, other stressful life events, or effects of psychotropic substances (van Os and Kapur, 2009; van Os et al., 2008, 2010).”
BackgroundTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Psychiatric Comorbidities and Schizophrenia
Buckley, P. F., Miller, B. J., Lehrer, D. S., & Castle, D. J. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn135 · Cited by 1,121 · cited 1×
“…have a high lifetime risk of about 25% for comorbid OCS and a recent meta-analysis reports that 12.1% also fulfill the criteria for an OCD (Figure 1C; Poyurovsky et al., 2004, 2012; Buckley et al., 2009; Lysaker and Whitney, 2009; Mukhopadhaya et al., 2009; Achim et al., 2011; Hadi et al., 2011).”
BackgroundInfluentialPractice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028 · cited 1×
“…and case series can hardly be reconciled with the fact, that CBT including exposure and response prevention is considered treatment of first choice for primary OCD with remarkably high effect sizes (Gava et al., 2007; Koran et al., 2007; Rosa-Alcazar et al., 2008; Kuelz and Voderholzer, 2011).”
Backgroundvan Os, J., Rutten, B. P., & Poulton, R. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn117 · Cited by 713
Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635 · cited 1×
“Furthermore, antiobsessive effects of antipsychotics have also been reported in primary OCD, including OLZ, especially in cases with treatmentresistance to serotonergic antidepressants (Bloch et al., 2006; Bandelow et al., 2008; Dold et al., 2011; Muscatello et al., 2011).”
BackgroundFusar-Poli, P., Nelson, B., Valmaggia, L., Yung, A. R., & McGuire, P. K. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs136 · Cited by 589 · cited 3×
“Whereas higher impairment of psychosocial functioning (de Haan et al., 2012; DeVylder et al., 2012; Fusar-Poli et al., 2012; Hur et al., 2012) and more severe depressive symptoms (Niendam et al., 2009; DeVylder et al., 2012; Fontenelle et al., 2012; de Haan et al., 2013) have consistently been…”
BackgroundResultA meta-analysis of functional neuroimaging in obsessive-compulsive disorder
Whiteside, S. P., Port, J. D., & Abramowitz, J. S. (2004) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2004.07.001 · Cited by 520
How psychotherapy changes the brain – the contribution of functional neuroimaging
Linden, D. E. J. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001816 · Cited by 491
Psychological treatment of obsessive–compulsive disorder: A meta-analysis
Rosa-Alcázar, A. I., Sánchez-Meca, J., Gómez-Conesa, A., & Marín-Martínez, F. (2008) · Clinical Psychology Review · doi:10.1016/j.cpr.2008.07.001 · Cited by 444
Neuropsychological performance in obsessive-compulsive disorder: a critical review
Kuelz, A. K., Hohagen, F., & Voderholzer, U. (2004) · Biological Psychology · doi:10.1016/j.biopsycho.2003.07.007 · Cited by 436
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314 · cited 1×
“…Yang and Lu, 2011), human MR spectroscopy (Whiteside et al., 2006; Starck et al., 2008), treatment approaches addressing the glutamatergic system (Coric et al., 2005; Poyurovsky et al., 2005, 2010; Lafleur et al., 2006; Pittenger et al., 2006) and the following results from genetic…”
BackgroundDickel, D. E., Veenstra-VanderWeele, J., Cox, N. J., Wu, X., Fischer, D. J., Van Etten-Lee, M., Himle, J. A., Leventhal, B. L., Cook, E. H., & Hanna, G. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.778 · Cited by 274
Gene–environment interactions: early life stress and risk for depressive and anxiety disorders
Nugent, N. R., Tyrka, A. R., Carpenter, L. L., & Price, L. H. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2151-x · Cited by 269 · cited 2×
“GxEIs are core elements within current theories of schizophrenia (van Os and Kapur, 2009; van Os et al., 2008, 2010), depression (Keers and Uher, 2012), anxiety disorders (Gregory et al., 2008; Nugent et al., 2011) and OCD (Nicolini et al., 2009; Pauls, 2010).”
BackgroundAssociation of the SLC1A1 glutamate transporter gene and obsessive‐compulsive disorder
Stewart, S. E., Fagerness, J. A., Platko, J., Smoller, J. W., Scharf, J. M., Illmann, C., Jenike, E., Chabane, N., Leboyer, M., Delorme, R., et al. (2007) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30533 · Cited by 182
Current animal models of obsessive compulsive disorder: a critical review
Joel, D. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.006 · Cited by 168 · cited 1×
“…neurotransmission, have also been related to OCD: Support for the involvement of glutamate in the development of OCD comes from animal models (Joel, 2006; Albelda et al., 2010; Yang and Lu, 2011), human MR spectroscopy (Whiteside et al., 2006; Starck et al., 2008), treatment approaches…”
BackgroundPsychological treatments versus treatment as usual for obsessive compulsive disorder (OCD)
Gava, I., Barbui, C., Aguglia, E., Carlino, D., Churchill, R., De Vanna, M., & McGuire, H. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005333.pub2 · Cited by 151 · cited 1×
“…and case series can hardly be reconciled with the fact, that CBT including exposure and response prevention is considered treatment of first choice for primary OCD with remarkably high effect sizes (Gava et al., 2007; Koran et al., 2007; Rosa-Alcazar et al., 2008; Kuelz and Voderholzer, 2011).”
Backgroundvan der Wee, N. J., Stevens, H., Hardeman, J. A., Mandl, R. C., Denys, D. A., van Megen, H. J., Kahn, R. S., & Westenberg, H. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.12.2201 · Cited by 149 · cited 1×
“However, apart from serotonergic dysfunctions, alterations in dopaminergic activity (Van der Wee et al., 2004) and in glutamatergic neurotransmission, have also been related to OCD: Support for the involvement of glutamate in the development of OCD comes from animal models (Joel, 2006; Albelda et…”
Wendland, J. R., Moya, P. R., Timpano, K. R., Anavitarte, A. P., Kruse, M. R., Wheaton, M. G., Ren-Patterson, R. F., & Murphy, D. L. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.6 · Cited by 145
The association between traumatic brain injury and ADHD in a Canadian adult sample
Ilie, G., Vingilis, E. R., Mann, R. E., Hamilton, H., Toplak, M., Adlaf, E. M., Kolla, N., Ialomiteanu, A., van der Mass, M., Asbridge, M., et al. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.08.004 · Cited by 128
Muscatello, M. R. A., Bruno, A., Pandolfo, G., Micò, U., Scimeca, G., Romeo, V. M., Santoro, V., Settineri, S., Spina, E., & Zoccali, R. A. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820e3db6 · Cited by 122 · cited 3×
“…pro-obsessive effects of predominantly anti-serotonergic SGAs, the add-on of mainly dopaminergic SGAs such as AMS and APZ has been proposed (Connor et al., 2005; Zink et al., 2006; Englisch and Zink, 2008; Kim et al., 2008; Yang et al., 2008; Englisch et al., 2009; Muscatello et al., 2011).”
BackgroundMethodShugart, Y. Y., Wang, Y., Samuels, J. F., Grados, M. A., Greenberg, B. D., Knowles, J. A., McCracken, J. T., Rauch, S. L., Murphy, D. L., Rasmussen, S. A., et al. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30914 · Cited by 112
Gene–Environment Interaction in Major Depression and Antidepressant Treatment Response
Keers, R., & Uher, R. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-011-0251-x · Cited by 94
Rajender, G., Bhatia, M. S., Kanwal, K., Malhotra, S., Singh, T. B., & Chaudhary, D. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01733.x · Cited by 84
The neuropsychology of the schizo-obsessive subtype of schizophrenia: a new analysis
Patel, D. D., Laws, K. R., Padhi, A., Farrow, J. M., Mukhopadhaya, K., Krishnaiah, R., & Fineberg, N. A. (2010) · Psychological Medicine · doi:10.1017/s0033291709991255 · Cited by 82
Veenstra-VanderWeele, J., Kim, S.-J., Gonen, D., Hanna, G. L., Leventhal, B. L., & Cook, E. H. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000806 · Cited by 74
DeVylder, J. E., Oh, A. J., Ben-David, S., Azimov, N., Harkavy-Friedman, J. M., & Corcoran, C. M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.07.009 · Cited by 55 · cited 3×
“Whereas higher impairment of psychosocial functioning (de Haan et al., 2012; DeVylder et al., 2012; Fusar-Poli et al., 2012; Hur et al., 2012) and more severe depressive symptoms (Niendam et al., 2009; DeVylder et al., 2012; Fontenelle et al., 2012; de Haan et al., 2013) have consistently been…”
BackgroundResultLee, M.-J., Shin, Y.-B., Sunwoo, Y.-K., Jung, S.-H., Kim, W.-H., Kang, M.-H., Lee, J.-S., Bae, J.-N., & Kim, C.-E. (2009) · Psychiatry Investigation · doi:10.4306/pi.2009.6.4.286 · Cited by 49 · cited 1×
“…and Ozkorumak, 2010; Achim et al., 2011; Meijer et al., 2013), others even suggested that OCS may be associated with better cognitive abilities (Lee et al., 2009; Borkowska et al., 2013), especially in the prodromal states of schizophrenia (Van Dael et al., 2011; Fontenelle et al., 2012; Hur…”
BackgroundYang, X. W., & Lu, X.-H. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834451fb · Cited by 36
Cited by
Schizo-obsessive spectrum disorders: an update
Scotti-Muzzi, E., & Saide, O. L. (2017) · CNS Spectrums · doi:10.1017/s1092852916000390 · Cited by 65
Obsessive-compulsive symptoms in schizophrenia: an up-to-date review of literature
Tezenas du Montcel, C., Pelissolo, A., Schürhoff, F., & Pignon, B. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1051-y · Cited by 61
Jeon, S., Baek, J. H., Yang, S. Y., Choi, Y., Ahn, S. W., Ha, K., & Hong, K. S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.08.012 · Cited by 34
Szmulewicz, A., Samamé, C., Caravotta, P., Martino, D. J., Igoa, A., Hidalgo-Mazzei, D., Colom, F., & Strejilevich, S. A. (2016) · International Journal of Bipolar Disorders · doi:10.1186/s40345-016-0047-3 · Cited by 28
Obsessive-Compulsive, Psychotic, and Autism Dimensions Overlap in Real World: A Case Report
Scala, M., Biondi, L., Serretti, A., & Fabbri, C. (2023) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000561 · Cited by 7
Metadata
- Authors
- Schirmbeck, F., & Zink, M.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 4
- Pages
- 99-99
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2060233596
- Cited by
- 118
- References
- 30
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.